On April 22, 2024, iBio Inc, a biotechnology company, received communication from the Division of Corporation Finance Office of Life Sciences at the United States Securities and Exchange Commission (SEC). The SEC informed iBio Inc's Chief Financial Officer, Felipe Duran, that its Registration Statement on Form S-3, filed on April 16, 2024, with the file number 333-278729, will not be reviewed by the staff. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of disclosures in the registration statement. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC provided contact information for Jimmy McNamara. The notice concluded with a reminder of the company's responsibility for its disclosures, irrespective of the SEC's review process.

On April 22, 2024, iBio Inc, a biotechnology company, received communication from the Division of Corporation Finance Office of Life Sciences at the United States Securities and Exchange Commission (SEC). The SEC informed iBio Inc's Chief Financial Officer, Felipe Duran, that its Registration Statement on Form S-3, filed on April 16, 2024, with the file number 333-278729, will not be reviewed by the staff. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of disclosures in the registration statement. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC provided contact information for Jimmy McNamara. The notice concluded with a reminder of the company's responsibility for its disclosures, irrespective of the SEC's review process.